Inclusion Criteria:

          -  Cytologically or histologically and radiologically confirmed solid tumor that is
             inoperable, locally advanced, metastatic, or recurrent.

          -  Dose-Escalation Stage Cohort A and Cohort-Expansion Stage (Cohorts B - G): The subject
             has received standard life-prolonging therapies unless they do not exist, or available
             therapies are intolerable or no longer effective.

          -  Cohort-Expansion Stage Cohort B (Non-small Cell Lung Cancer): Subjects with Stage IV
             NSCLC who have documented radiographic disease progression during or following their
             last systemic anticancer therapy.

          -  Cohort-Expansion Stage Cohort C (Urothelial Cancer): Subjects with transitional cell
             histology (including renal pelvis, ureter, urinary bladder, urethra) who have
             documented radiographic disease progression during or following their last systemic
             anticancer therapy.

          -  Cohort-Expansion Stage Cohort D (Epithelial Ovarian Cancer): Subjects with epithelial
             ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer
             (FTC) who have platinum-resistant disease following treatment with platinum-containing
             chemotherapy. Note: Ovarian borderline epithelial tumors (low malignant potential) are
             not eligible.

          -  Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with carcinoma of the
             uterine cervix who have documented radiographic disease progression during or
             following their last systemic anticancer therapy.

          -  Cohort F (SCCHN): Subjects with head and neck cancer (squamous cell histology) who
             have documented radiographic disease progression during or following their last
             systemic anticancer therapy. Allowed primary tumor locations are oral cavity,
             oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary
             tumor site of the nasopharynx.

          -  Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma
             histology) who have documented radiographic disease progression during or following
             their last systemic anticancer therapy.

          -  Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined
             by the Investigator.

          -  Tumor tissue material collected approximately 2 years prior to consent. If archival
             tumor tissue is not available, a fresh tumor biopsy may be collected from subjects
             enrolled in the Dose-Escalation Stage and must be collected from subjects in the
             Cohort-Expansion Stage, at least 7 days (and up to 60 days) prior to first dose.

          -  Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse
             Events version 5 [CTCAE v5]) from AEs.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

          -  Adequate organ and marrow function.

          -  Sexually active fertile subjects and their partners must agree to use medically
             accepted methods of contraception.

          -  Female subjects of childbearing potential must not be pregnant at screening.

        Exclusion Criteria:

          -  Receipt of prior therapies as defined in study protocol

          -  Known brain metastases or cranial epidural disease unless adequately treated with
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks
             before first dose of study treatment.

          -  Uncontrolled, significant intercurrent or recent illness.

          -  Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per
             electrocardiogram (ECG).

          -  Pregnant or lactating females

          -  Diagnosis of another malignancy within 2 years before first dose of study treatment,
             except for superficial skin cancers, or localized, low grade tumors deemed cured and
             not treated with systemic therapy.